Moderna (CHIX:0QFD) Moat Score: 7/10 (As of Jul. 01, 2026)


CHIX:0QFD Moderna Inc CHIX:0QFD
58 GF Score
Price €63.59
GF Value €14.06
! 7 Warning Signs
View Full Analysis

What is Moderna Moat Score?

Moderna CHIX:0QFD +48.91% 58 Moat Score is 7 as of Jul. 01, 2026. GuruFocus rates CHIX:0QFD with a GF Score™ of 58/100 and a GF Value™ of €14.06. The stock has 7 warning signs investors should review. Among 1,401 Biotechnology companies, Moderna ranks better than 99.57% on this metric.

Moderna has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Moderna has Wide Moat: Moderna possesses a strong portfolio of mRNA technology and patents, providing significant intellectual property protection. Its R&D capabilities and innovation in vaccine development offer durable competitive advantages, supported by strong brand recognition and market leadership.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Moderna might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Moderna  (CHIX:0QFd) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Moderna Moat Score Related Terms

CHIX:0QFD vs RPRX, ROIV, ONC: Moat Score Comparison

For the Biotechnology subindustry, Moderna's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moderna Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's Moat Score distribution charts can be found below:

* The bar in red indicates where Moderna's Moat Score falls into.


CHIX:0QFD
58GF Score
Moderna Inc CHIX:0QFD
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
Moderna (CHIX:0QFD) has a Moat Score of 7 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Moderna ranks #6 out of 1401 companies in the Biotechnology industry, placing it in the top 0.40000000000001%.
Is Moderna's Moat Score too high?
Moderna's current Moat Score is 7. The Biotechnology industry median Moat Score is 2.00. Moderna's value of 7 is 250% above this industry median. Based on the distribution chart, Moderna ranks #6 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Moderna has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Moderna's Moat Score compare to RPRX and ROIV?
According to the Biotechnology industry distribution chart, Moderna ranks #6 out of 1401 companies for Moat Score. This places Moderna in the top 0% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Moderna's value of 7 is 250% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moderna's current Moat Score of 7 is 250% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moderna's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moderna stock overvalued right now?
Moderna (CHIX:0QFD) has a current Moat Score of 7. The stock's GF Value™ is €14.06, compared to a current price of €63.59 — trading 352.3% above its estimated fair value. The current Moat Score is 7 and 250% above the Biotechnology industry median of 2.00. Moderna's overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Moderna (CHIX:0QFD), the current Moat Score is 7 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moderna (CHIX:0QFD) Overvalued in 2026?

Based on GuruFocus' analysis, Moderna stock appears to be overvalued. The current stock price of €63.59 is trading 352.3% above its estimated GF Value™ of €14.06.

Key valuation signals for CHIX:0QFD:

  • Moat Score: 7
  • GF Value™: €14.06 vs. price of €63.59 (352.3% above fair value)
  • GF Score™: 58/100 with 7 warning signs
  • Industry Position: 250% above the Biotechnology median (#6 of 1401)

No single metric tells the full story. See the CHIX:0QFD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moderna Business Description

Address 325 Binney Street, Cambridge, MA, USA, 02142
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
58GF Score

Get the complete analysis for CHIX:0QFD

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€63.59
Price
€14.06
GF Value